hematologic disorders in chd
TRANSCRIPT
![Page 1: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/1.jpg)
CCHD - A Multi-System Systemic Disorder
![Page 2: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/2.jpg)
The First Step
Perloff JK, Jacobsen J, Rath CE Intravascular hemolysis and thrombocytopenia
in left ventricular outflow obstruction. Br. Heart J. 1973
Decades Ago
![Page 3: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/3.jpg)
The Second Step 2011
The Hematologic Disorders of
Congenital Heart Disease
![Page 4: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/4.jpg)
Hematologic Disorders
1) The red blood cell: a) Mass b) Iron deficiency c) Nitric oxide d) Bilirubin kinetics 2) Platelets/Megakaryocytes 3) Hemorrhagic diatheses: a) Vasodilatation b) Hemostatic defects
![Page 5: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/5.jpg)
Increased Red Cell Mass
Primary--Polycythemia rubra vera is a malignant clonal stem cell disorder characterized by excessive proliferation of all three hematopoietic cell lines---erythroid, myeloid and megakaryocytic. Secondary--In CCHD, a desirable adaptation to hypoxemia is characterized by an isolated increase in red cell mass.
![Page 6: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/6.jpg)
Erythropoietin
Erythropoieten is the major regulator of red cell production in the bone marrow. Its concentration is determined by oxygen availability in the renal cortex, the major site of production. The hypoxemic stimulus of CCHD elevates serum erythropoietin levels. When the increase in red cell mass is adequate to offset tissue hypoxemia, erythropoietin levels normalize.
![Page 7: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/7.jpg)
Why Does Red Cell Mass Increase in Cyanotic Congenital Heart Disease?
Nature is neither lazy nor devoid of foresight. Galen
Erythrocytosis is a desirable compensatory adaptation to systemic arterial hypoxemia and to a decrease in tissue oxygenation.
Phlebotomy reduces red cell mass, reduces tissue oxygen delivery, and stimulates release of erythropoietin.
![Page 8: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/8.jpg)
Iron Deficiency
When deformable biconcave discs become
non-deformable iron deficient microspherocytes,
whole blood viscosity increases 100 times at a
hematocrit of 70%.
![Page 9: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/9.jpg)
Precautions Micro-hematocrit centrifugation in the presence of erythrocytosis results in plasma trapping and false elevation of hematocrit levels. Hematocrit should therefore be based on automated electronic particle counts. The standard amount of citrate anticoagulant added to a normal blood sample is excessive because plasma volume is decreased in the presence of erythrocytosis. The amount of citrate must therefore be adjusted.
![Page 10: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/10.jpg)
Chronic Hypoxaemia and Decompensated Erthrocytosis in CCHD Rosove, Perloff et al, The Lancet 1986
Compensated Erythrocytosis--Physiologic adaptation to tissue hypoxemia is established with equilibrium hematocrits and an iron replete state. Decompensated Erythrocytosis-- Iron replete equilibrium hematocrits and physiologic adaptation to tissue hypoxemia are not established.
![Page 11: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/11.jpg)
Beneficial Effects of Erythrocytosis
The erythrocytosis accompanying CCHD is a beneficial adaptive response to systemic arterial hypoxemia, serving to increase oxygen delivery to metabolizing tissues. Oxygen delivery is further increased by systemic vasodilatation in response to elaboration of endothelial NO which is increased by the shear stress of the erythrocytotic perfusate.
![Page 12: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/12.jpg)
Nitric Oxide
The molecule diffuses from vascular endothelium according to Fickian principles. Abluminal diffusion regulates blood flow by activating soluble guanylate cyclase in medial smooth muscle cells. However, a significant fraction of NO diffuses luminally where it is regulated by the extremely high reaction rate with red cell hemoglobin, rendering the effective luminal concentration zero.
Han and Perloff
![Page 13: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/13.jpg)
T o t a l N O µM
Tae, Perloff, Liao Total NO is increased in the plasma of adults with CCHD.
![Page 14: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/14.jpg)
Red cell nitrosyl-hemoglobin (HbNO) concentration is increased in adults with CCHD.
![Page 15: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/15.jpg)
Han, Perloff, Liao
Luminal diffusion of NO culminates in rapid inactivation by red cell Hg. An increase in red cell mass in CCHD results in increased NO inactivation, less abluminal diffusion, and less vasodilatation.
![Page 16: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/16.jpg)
Nitric Oxide and Red Blood Cell Deformability
Red cell deformability is enhanced by
physiologic concentrations of NO, facilitating oxygen release and delivery of oxygen to
metabolizing tissue.
![Page 17: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/17.jpg)
Gilbert’s Disease An Experiment of Nature
An inborn error of bilirubin metabolism
characterized by a benign elevation of unconjugated bilirubin without liver
disease or hematologic abnormalities.
![Page 18: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/18.jpg)
Bilirubin Kinetics
• Bilirubin is formed from the breakdown of heme, a process that is excessive in the presence of the erythrocytosis of CCHD, and that coincides with a substantial increase in unconjugated bilirubin which is a natural anti-oxidant that is antiatherogenic.
Ahmanson/UCLA Adult Congenital Heart Disease Center
![Page 19: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/19.jpg)
Ahmanson/UCLA Adult Congenital Heart Disease Center
Typical total bilirubin
level in CCHD
3.7
Reference Level
0-1.0 mg/dL
Jaundice in CCHD
![Page 20: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/20.jpg)
![Page 21: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/21.jpg)
Blood Letting Ancient History
![Page 22: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/22.jpg)
An Anachronistic Benefit of Bloodletting
When Madame de Manenon became the consort of Louis IV, her physician removed
one or two ounces of blood several times a week so madame would not blush so readily at the stories told in
the French royal court.
![Page 23: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/23.jpg)
Current Criteria for Phlebotomy
Phlebotomy should be reserved for temporary relief of hyperviscosity symptoms, and should not be based on hematocrit per se irrespective of level. The assumed risk of stroke due to cerebral arterial thrombosis in CCHD has not materialized whether erythrocytosis is iron replete or iron deficient.
![Page 24: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/24.jpg)
Technique of Phlebotomy
The amount of blood removed is the minimum needed to achieve symptomatic relief of hyperviscosity symptoms, generally one unit followed by isovolumetric saline replacement.
Oral hydroxyurea blunts phlebotomy- induced rebound of erythropoietin.
![Page 25: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/25.jpg)
Iron Deficiency A Caveat
Iron deficiency in CCHD sometimes occurs without hyochromia or microcytosis
because a coexisting elevation of homocystine causes an increase in both red cell size and
color. Kaemmerer, et al. Am J Cardiol 2005
![Page 26: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/26.jpg)
Metabolic Effects of Iron Deficiency
Iron is an integral part of myoglobin and of certain mitochondrial enzymes, and plays an important role in oxidative metabolism. Because of the metobolic effect of iron, the myalgias and muscle weakness of iron deficiency disappear promptly after administration of intravenous iron dextran, i.e. before iron stores are replete.
![Page 27: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/27.jpg)
Management of Iron Deficiency Because erythropoietin levels are elevated in patients with phlebotomy-induced iron deficiency, administraton of iron results in a rapid rise in red cell mass. Accordingly, the therapeutic dose of iron should be small, and monitoring should be frequent. Iron should be stopped at the first discernible rise in hematocrit.
![Page 28: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/28.jpg)
Increased risk in infants with iron deficient erythrocytosis
Thrombus
Cerebral Venous Thrombotic Stroke
![Page 29: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/29.jpg)
Hyperviscosity Symptoms
Headache, faintness, dizziness. Lightheadedness, slow mentation. Impaired alertness, a sense of distance or dissociation.
Paraesthesiae, tinnitus, anorexia. Blurred vision, double vision, scotomata. .
Myalgias, muscle weakness. Fatigue, lassitude, lethargy.
Symptoms of Iron Deficiency
![Page 30: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/30.jpg)
Proximal Pulmonary Arterial Thrombosis in Eisenmenger
Syndrome
Thrombus
![Page 31: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/31.jpg)
Massive Proximal Pulmonary Arterial Thrombus in
Eisenmenger Syndrome
Intra-pulmonary Embolization from Proximal Thrombus
![Page 32: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/32.jpg)
Hartman RC. A Hemorrhagic Disorder Occurring in Patients with Cyanotic
Congenital Heart Disease. Bull Johns Hopkins Hospital 1952
“The temptation to use the anticoagultant drugs may be great. On the basis of the present studies, their use would appear to be fraught with danger.”
![Page 33: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/33.jpg)
Proximal Pulmonary Arterial Thrombosis
A Therapeutic Dilemma
The efficacy of anticoagulants is nil, while the risk of reinforcing hemostatic defect(s) and provoking
hemorrhage is considerable. The efficacy of thrombolytic agents, including intrapulmonary administration, is nil.
![Page 34: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/34.jpg)
Abnormal Hemostasis in Cyanotic Congenital Heart Disease
Increased tissue vascularity
Intrinsic hemostatic defects
![Page 35: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/35.jpg)
Kohler et al Circulation Research 1993
The viscous erythrocytotic perfusate in CCHD is associated with an increase in endothelial shear stress, elaboration of NO, arterial dilatation, and increased tissue vascularity.
Ahmanson/UCLA Adult Congenital Heart Disease Center
![Page 36: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/36.jpg)
Intrinsic Hemostatic Defects
2) Decreased levels of fibrinogen and factors V, VII, VIII, IX. 3) Elevated levels of fibrin degradation products. 1) Prolongation of prothrombin time, activated partial
thromboplastin time, and bleeding time. 4) Low platelet counts and thrombocytopenia. 5) Von Willebrand factor abnormalities.
![Page 37: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/37.jpg)
There’s something ominous about blood coming from the mouth like the glow of a fire. Anton Chekhov about himself
Extra-Pulmonary Hemorrhage (Hemoptysis)
![Page 38: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/38.jpg)
Intrapulmonary
Hemorrhage
![Page 39: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/39.jpg)
Pulmonary Hemorrhage
Complications of pulmonary hemorrhage vary from mild and occasional to copious, recurrent, massive, and fatal. Eisenmenger’s patient (1897) died suddenly following a large hemoptysis. Massive intrapulmonary hemorrhage is the commonest cause of sudden death in Eisenmenger syndrome.
![Page 40: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/40.jpg)
Management of Hemoptysis
1. Do not bronchoscope. 2. Antiplatelet or anti-inflamatory agents are
questionable. 3. Chest x-ray for detection of
intrapulmonary hemorrhage.
4. CT scan if x-ray detects infiltrates. 5. Hospitalize if intrapulmonary hemorrhage
is moderate or greater.
![Page 41: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/41.jpg)
Management contd.
1. Thrombocytopenia – platelet transfusion. 2. Normal Platelet Count : a) Fresh frozen plasma. b) Cryoprecipitate. 3. Excessively low hematocrit--- red cell transfusion.
![Page 42: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/42.jpg)
Eisenmenger Syndrome and Pregnancy Hematologic Issues
![Page 43: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/43.jpg)
Heparin During Pregnancy
Caveats 1. Hypercoagulability does not occur in
the first or second trimester, and is variable during the third trimester
2. Heparin is an antiplatelet agent. Platelet counts are low-normal or
thrombocytopenic. 3. There are no reliable tests for
measuring thrombin generation or antithrombin levels.
![Page 44: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/44.jpg)
Heparin Caveats, contd.
In brief: Heparin pharmacokinetics are complex, and the hemostatic substrate in gravidas with CCHD is variable. The risks of heparin far outweigh theoretical benefits.
Conclusion: Proceed With Caution
![Page 45: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/45.jpg)
LABOR
A hypercoagulable state is indicated by enhanced platelet activation and elevated
fibrinogen and factor VII.
![Page 46: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/46.jpg)
Hypercoagulability continues through the first postpartum day, but fibrin residues are cleared by
enhanced fibrinolysis.
Postpartum
![Page 47: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/47.jpg)
The Von Willebrand Factor (vWF)
vWF is a large, multimeric glycoprotein in plasma, in platelets, and in vascular endothelial cells. The vWF
plays a central role in hemostasis, is a major adhesive link between vascular subendothelium and platelets,
and is a carrier for factor VIII procoagulant.
Territo, Perloff et al. 1998
![Page 48: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/48.jpg)
The von Willebrand Factor in Congenital Heart Disease
A relative decrease in or loss of the largest vWF multimetric forms occurs in 70% to 77% of patients with cyanosis, pulmonary vascular disease or tubulant blood flow. Depletion normalizes after reparative surgery, indicating that the vWF abnormality is acquired and reversible.
![Page 49: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/49.jpg)
Agarose Gel Electrophorisis
![Page 50: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/50.jpg)
Paucity of Coronary Atherosclerosis in CCHD
Hypocholesterolemia Hypoxemia
Low platelet counts Up-regulated nitric oxide
Bilirubin
Ahmanson/UCLA Adult Congenital Heart Disease Center
![Page 51: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/51.jpg)
Each cubic millimeter of blood contains about 250 million platelets that survive about 10
days after they are released into the circulation.
Platelets
![Page 52: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/52.jpg)
Platelet Counts
Low platelet counts and thrombocytopenia are common in
CCHD. Platelet production is decreased because of ineffective thrombopoiesis,
not because of increased platelet destruction or activation.
Ahmanson/UCLA Adult Congenital Heart Disease Center
![Page 53: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/53.jpg)
Platelet Production 1) Whole megakaryocytes leave the bone marrow and
enter the systemic venous circulation. 2) Platelets are produced by fragmentation of the
cytoplasm of circulating megakaryocytes during their pulmonary transit.
Nucleus
Bone Marrow
![Page 54: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/54.jpg)
Megakaryocyte Lodged in Digital
Capillary
Megakaryocyte Leaving Bone Marrow
![Page 55: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/55.jpg)
Leaving the Marrow
Lodged in a Pulmonary Capillary
In Bone Marrow
Perloff, Latta, Barsatti. Am J Cardiol 2000
Megakaryocytes
![Page 56: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/56.jpg)
Nitric Oxide and the Kidney in CCHD
NO is synthesized in the cytosol of mesangeal cells and glomerular capillary endothelial cells. The molecule functions as an autocrine hormone that modulates the glomerular response to the increased perfusion resistance of erythrocytosis. Arterioles and capillaries dilate. Glomerular vascularity, blood flow, and size increase.
![Page 57: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/57.jpg)
Normal Glomeruli
Cap
RBC Mes. Cell
Light Microscopy
Electron Microscopy
![Page 58: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/58.jpg)
The cytoplasm of intact shunted systemic venous megakaryocytes carries PDGF and TGF beta to the digits, the periostium, and to the glomerular capillaries. These mitogens and cytokines act locally because of their short half life, stimulating mesenchymally derived cells, enhancing connective tissue formation, promoting protein synthesis, extracellular matrix, fibrosis and cell proliferation, and causing clubbing, hypertrophic osteoarthropathy, and the non-vascular glomerular abnormality.
The Pathogenesis of Clubbing, Hypertrophic Osteoarthropathy, and the Non-vascular Glomerular
Abnormality
![Page 59: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/59.jpg)
Digits and Long Bones
Megakaryocyte in Digital Capillary
![Page 60: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/60.jpg)
Technetium 99m Bone Scan Increased Tracer in Clubbed Distal Phalanges
![Page 61: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/61.jpg)
Hypertrophic Osteoarthrophy
Sub-periostial Technetium 99m Uptake
Long Bones
![Page 62: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/62.jpg)
Non-vascular
Vascular
Glomerular Abnormalities
![Page 63: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/63.jpg)
Spongy Fragile Gums
![Page 64: Hematologic Disorders in CHD](https://reader031.vdocument.in/reader031/viewer/2022020314/58904c671a28aba64e8bc91d/html5/thumbnails/64.jpg)
CCHD - A Multi-System Systemic Disorder